vs
Amarin Corp plc（AMRN）与ALTISOURCE PORTFOLIO SOLUTIONS S.A.（ASPS）财务数据对比。点击上方公司名可切换其他公司
Amarin Corp plc的季度营收约是ALTISOURCE PORTFOLIO SOLUTIONS S.A.的1.1倍（$45.1M vs $42.3M），ALTISOURCE PORTFOLIO SOLUTIONS S.A.净利率更高（-16.8% vs -23.3%，领先6.4%），Amarin Corp plc同比增速更快（7.0% vs 3.2%），过去两年ALTISOURCE PORTFOLIO SOLUTIONS S.A.的营收复合增速更高（3.6% vs -18.3%）
Amarin是一家1993年成立的爱裔美籍生物制药企业，总部分别设于爱尔兰都柏林与美国新泽西州布里奇沃特。该企业专注研发及销售心血管疾病治疗药物，已推出处方级Omega-3脂肪酸药物Vascepa（AMR-101）。
Altisource Portfolio Solutions S.A.是面向抵押贷款、房地产及消费金融领域的全球服务商，为贷款机构、服务商、投资者等市场参与者提供技术、数据与运营解决方案，优化资产管理、房产交易等业务流程，提升客户运营效率。
AMRN vs ASPS — 直观对比
营收规模更大
AMRN
是对方的1.1倍
$42.3M
营收增速更快
AMRN
高出3.8%
3.2%
净利率更高
ASPS
高出6.4%
-23.3%
两年增速更快
ASPS
近两年复合增速
-18.3%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $45.1M | $42.3M |
| 净利润 | $-10.5M | $-7.1M |
| 毛利率 | — | 26.5% |
| 营业利润率 | 35.5% | -15.5% |
| 净利率 | -23.3% | -16.8% |
| 营收同比 | 7.0% | 3.2% |
| 净利润同比 | 33.0% | 18.2% |
| 每股收益（稀释后） | — | $-1.02 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AMRNASPS
| Q1 26 | $45.1M | — | ||
| Q4 25 | $49.2M | $42.3M | ||
| Q3 25 | $49.7M | $41.9M | ||
| Q2 25 | $72.7M | $43.3M | ||
| Q1 25 | $42.0M | $43.4M | ||
| Q4 24 | $62.3M | $41.0M | ||
| Q3 24 | $42.3M | $40.5M | ||
| Q2 24 | $67.5M | $39.1M |
净利润AMRNASPS
| Q1 26 | $-10.5M | — | ||
| Q4 25 | $-1.2M | $-7.1M | ||
| Q3 25 | $-7.7M | $-2.3M | ||
| Q2 25 | $-14.1M | $16.7M | ||
| Q1 25 | $-15.7M | $-5.3M | ||
| Q4 24 | $-48.6M | $-8.7M | ||
| Q3 24 | $-25.1M | $-9.3M | ||
| Q2 24 | $1.5M | $-8.3M |
毛利率AMRNASPS
| Q1 26 | — | — | ||
| Q4 25 | 47.1% | 26.5% | ||
| Q3 25 | 44.7% | 27.1% | ||
| Q2 25 | 69.2% | 30.1% | ||
| Q1 25 | 59.8% | 30.7% | ||
| Q4 24 | -15.4% | 30.3% | ||
| Q3 24 | 38.5% | 29.8% | ||
| Q2 24 | 63.4% | 32.5% |
营业利润率AMRNASPS
| Q1 26 | 35.5% | — | ||
| Q4 25 | -12.9% | -15.5% | ||
| Q3 25 | -22.4% | 1.2% | ||
| Q2 25 | -22.0% | 7.5% | ||
| Q1 25 | -39.9% | 7.5% | ||
| Q4 24 | -84.3% | 1.4% | ||
| Q3 24 | -59.5% | 2.7% | ||
| Q2 24 | -0.8% | 5.3% |
净利率AMRNASPS
| Q1 26 | -23.3% | — | ||
| Q4 25 | -2.5% | -16.8% | ||
| Q3 25 | -15.6% | -5.5% | ||
| Q2 25 | -19.4% | 38.5% | ||
| Q1 25 | -37.4% | -12.1% | ||
| Q4 24 | -78.0% | -21.3% | ||
| Q3 24 | -59.4% | -23.0% | ||
| Q2 24 | 2.3% | -21.1% |
每股收益（稀释后）AMRNASPS
| Q1 26 | — | — | ||
| Q4 25 | $0.00 | $-1.02 | ||
| Q3 25 | $-0.02 | $-0.22 | ||
| Q2 25 | $-0.03 | $1.48 | ||
| Q1 25 | $-0.04 | $-0.09 | ||
| Q4 24 | $-0.12 | $-4.72 | ||
| Q3 24 | $-0.06 | $-2.61 | ||
| Q2 24 | $0.00 | $-2.33 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $307.8M | $26.6M |
| 总债务越低越好 | — | $191.1M |
| 股东权益账面价值 | — | $-110.2M |
| 总资产 | $645.8M | $139.8M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资AMRNASPS
| Q1 26 | $307.8M | — | ||
| Q4 25 | $302.6M | $26.6M | ||
| Q3 25 | $286.6M | $28.6M | ||
| Q2 25 | $298.7M | $30.0M | ||
| Q1 25 | $281.8M | $30.8M | ||
| Q4 24 | $294.2M | $29.8M | ||
| Q3 24 | $305.7M | $28.3M | ||
| Q2 24 | $306.7M | $29.7M |
总债务AMRNASPS
| Q1 26 | — | — | ||
| Q4 25 | — | $191.1M | ||
| Q3 25 | — | $192.5M | ||
| Q2 25 | — | $193.9M | ||
| Q1 25 | — | $195.0M | ||
| Q4 24 | — | $230.5M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
股东权益AMRNASPS
| Q1 26 | — | — | ||
| Q4 25 | $459.3M | $-110.2M | ||
| Q3 25 | $458.9M | $-104.2M | ||
| Q2 25 | $464.9M | $-102.7M | ||
| Q1 25 | $473.7M | $-119.8M | ||
| Q4 24 | $486.2M | $-157.4M | ||
| Q3 24 | $531.4M | $-149.4M | ||
| Q2 24 | $551.9M | $-140.8M |
总资产AMRNASPS
| Q1 26 | $645.8M | — | ||
| Q4 25 | $670.8M | $139.8M | ||
| Q3 25 | $659.8M | $139.9M | ||
| Q2 25 | $670.1M | $142.9M | ||
| Q1 25 | $655.7M | $145.7M | ||
| Q4 24 | $685.3M | $143.6M | ||
| Q3 24 | $750.6M | $144.5M | ||
| Q2 24 | $799.9M | $146.6M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $-505.0K |
| 自由现金流经营现金流 - 资本支出 | — | $-525.0K |
| 自由现金流率自由现金流/营收 | — | -1.2% |
| 资本支出强度资本支出/营收 | — | 0.0% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-5.1M |
8季度趋势，按日历期对齐
经营现金流AMRNASPS
| Q1 26 | — | — | ||
| Q4 25 | $15.3M | $-505.0K | ||
| Q3 25 | $-12.7M | $718.0K | ||
| Q2 25 | $16.6M | $-306.0K | ||
| Q1 25 | $-12.5M | $-5.0M | ||
| Q4 24 | $-13.3M | $-1.4M | ||
| Q3 24 | $-2.4M | $-1.6M | ||
| Q2 24 | $-2.7M | $180.0K |
自由现金流AMRNASPS
| Q1 26 | — | — | ||
| Q4 25 | — | $-525.0K | ||
| Q3 25 | — | $697.0K | ||
| Q2 25 | — | $-309.0K | ||
| Q1 25 | — | $-5.0M | ||
| Q4 24 | — | $-1.4M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
自由现金流率AMRNASPS
| Q1 26 | — | — | ||
| Q4 25 | — | -1.2% | ||
| Q3 25 | — | 1.7% | ||
| Q2 25 | — | -0.7% | ||
| Q1 25 | — | -11.5% | ||
| Q4 24 | — | -3.4% | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
资本支出强度AMRNASPS
| Q1 26 | — | — | ||
| Q4 25 | — | 0.0% | ||
| Q3 25 | — | 0.1% | ||
| Q2 25 | — | 0.0% | ||
| Q1 25 | — | 0.1% | ||
| Q4 24 | — | 0.0% | ||
| Q3 24 | — | 0.0% | ||
| Q2 24 | — | 0.0% |
现金转化率AMRNASPS
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | -0.02× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | -1.81× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AMRN
| U.S | $35.6M | 79% |
| Europe | $4.9M | 11% |
| Rest-of-World (ROW) | $2.8M | 6% |
| Licensing & Royalties | $1.8M | 4% |
ASPS
| Services | $39.9M | 94% |
| Revenue Relatedto Technology Platformsand Professional Services | $2.4M | 6% |
